Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for hepatocellular carcinoma: a meta-analysis

References

• Bray F , FerlayJ, SoerjomataramIet al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• El-Serag HB , KanwalF. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?Hepatology60(5), 1767–1775 (2014).
   PubMed Web of Science ®Google Scholar
• Bruix J , ShermanM. Management of hepatocellular carcinoma: an update. Hepatology53(3), 1020–1022 (2011).
   PubMed Web of Science ®Google Scholar
• Mazzaferro V , RegaliaE, DociRet al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Eng. J. Med.334(11), 693–699 (1996).
   PubMed Web of Science ®Google Scholar
• Poon RT , FanST, LoCMet al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann. Surg.235(3), 373–382 (2002).
   PubMed Web of Science ®Google Scholar
• Truty MJ , VautheyJN. Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann. Surg. Oncol.17(5), 1219–1225 (2010).
   PubMed Web of Science ®Google Scholar
• Facciorusso A , ServiddioG, MuscatielloN. Local ablative treatments for hepatocellular carcinoma: an updated review. World. J. Gastrointest. Pharmacol. Ther.7(4), 477 (2016).
   PubMedGoogle Scholar
• Lu Z , WenF, GuoQ, LiangH, MaoX, SunH. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials. Eur. J. Gastroenterol. Hepatol.25(2), 187–194 (2013).
   PubMed Web of Science ®Google Scholar
• Chen MS , LiJQ, ZhengYet al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann. Surg.243(3), 321–328 (2006).
   PubMed Web of Science ®Google Scholar
• Kalogeridi MA , ZygogianniA, KyrgiasGet al. Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review. World. J. Hepatol.7(1), 101–112 (2015).
   PubMedGoogle Scholar
• Sanuki N , TakedaA, KuniedaE. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World. J. Gastroenterol.20(12), 3100–3111 (2014).
   PubMed Web of Science ®Google Scholar
• Rim CH , YoonWS. Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials. Onco. Targets. Ther.11, 2865–2874 (2018).
   PubMed Web of Science ®Google Scholar
• Rajyaguru DJ , BorgertAJ, SmithALet al. Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: analysis of the national cancer database. J. Clin. Oncol.36(6), 600–608 (2018).
   PubMed Web of Science ®Google Scholar
• Wahl DR , StenmarkMH, TaoYet al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J. Clin. Oncol.34(5), 452 (2015).
   PubMed Web of Science ®Google Scholar
• Kim N , KimHJ, WonJYet al. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother. Oncol.131, 81–87 (2019).
   PubMed Web of Science ®Google Scholar
• Wells GA , SheaB, O'ConnellDet al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. OttawaHealthResearchInstitute (2000). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Xiao JC , GuoLM, KangXXet al. Comparison of efficiency and safety between radiofrequency ablation and stereotactic body radiotherapy on primary small hepatocellular carcinoma. Cancer. Res. Prev. Treat.44(12), 831–835 (2017).
   Google Scholar
• Zhou ZR , ZhangTS, LIBet al. Extracting and transforming of appropriate data of Meta-analysis in survival curve. Chin. J. Evid. Based. Cardiovasc. Med.6(3), 243–247 (2014).
   Google Scholar
• Tierney JF , StewartLA, GhersiDet al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials.8, 16 (2007).
   PubMed Web of Science ®Google Scholar
• Parmar MK , TorriV, StewartL. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist. Med.17(24), 2815–2834 (1998).
   PubMed Web of Science ®Google Scholar
• Higgins JP , ThompsonSG, DeeksJJet al. Measuring inconsistency in meta-analyses. BMJ.327(7414), 557–560 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang T , XieH, SunJet al. Clinical comparison of stereotactic body radiotherapy and radiofrequency ablation in the treatment of liver cancer. Infect. Dis. Info.29(4), 222–227 (2016).
   Google Scholar
• Pan YX , XiM, FuYZet al. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: a retrospective propensity score matching study. Cancers.11(8), 1116 (2019).
   PubMed Web of Science ®Google Scholar
• Parikh ND , MarshallVD, GreenMet al. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: an analysis of SEER-medicare. J. Med. Imaging. Radiat. Oncol.62(5), 673–681 (2018).
   PubMed Web of Science ®Google Scholar
• Hara K , TakedaA, TsurugaiYet al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. Hepatology69(6), 2533–2545 (2019).
   PubMed Web of Science ®Google Scholar
• Shiozawa K , WatanabeM, IkeharaTet al. Comparison of percutaneous radiofrequency ablation and CyberKnife ((R)) for initial solitary hepatocellular carcinoma: a pilot study. World. J. Gastroenterol.21(48), 13490–13499 (2015).
   PubMed Web of Science ®Google Scholar
• Kim N , ChengJ, JungIet al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J. Hepatol.73(1), 121–129 (2020).
   PubMed Web of Science ®Google Scholar
• Jeong Y , LeeKJ, LeeSJet al. Radiofrequency ablation versus stereotactic body radiation therapy for small (≤3 cm) hepatocellular carcinoma: a retrospective comparison analysis. J. Gastroen. Hepatol.doi: 10.1111/jgh.15442 (2021).
   Web of Science ®Google Scholar
• Fleming TR . Surrogate endpoints and FDA's accelerated approval process. Health. Aff.24(1), 67–78 (2005).
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver . EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma. J. Hepatol.56(4), 908–943 (2012).
   PubMed Web of Science ®Google Scholar
• Tabrizian P , JibaraG, ShragerBet al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann. Surg.261(5), 947–955 (2015).
   PubMed Web of Science ®Google Scholar
• Jang WI , KimMS, BaeSHet al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat. Oncol.8, 250 (2013).
   PubMed Web of Science ®Google Scholar
• Hong JW , CaoLP, XieHYet al. Stereotactic body radiation therapy versus radiofrequency ablation in patients with small hepatocellular carcinoma: a systematic review and meta-analysis. HepatoBiliary. Surg. Nutr.http://dx.doi.org/10.21037/hbsn.2020.03.15 (2020).
   Web of Science ®Google Scholar
• Lee JS , ShinIS, YoonWSet al. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review. Radiother. Oncol.145, 63–70 (2020).
   PubMed Web of Science ®Google Scholar
• Sutherland LM , WilliamsJA, PadburyRTet al. Radiofrequency ablation of liver tumors: a systematic review. Arch. Surg.141(2), 181–190 (2006).
   PubMedGoogle Scholar
• Ohri N , TomeWA, MéndezRomero Aet al. Local control after stereotactic body radiation therapy for liver tumors. Int. J. Radiat. Oncol. Biol. Phys.110(1), 188–195 (2021).
   PubMed Web of Science ®Google Scholar
• Liu HY , LeeY, McLeanKet al. Efficacy and toxicity of stereotactic body radiotherapy for early to advanced stage hepatocellular carcinoma-initial experience from an Australian liver cancer service. Clin. Oncol.32(10), e194–e202 (2020).
   Web of Science ®Google Scholar
• Dobrzycka M , SpychalskiP, RostkowskaOet al. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma-a systematic review on outcome. Acta. Oncol.58(12), 1706–1713 (2019).
   PubMed Web of Science ®Google Scholar
• Kim JW , SeongJ, LeeIJet al. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. Oncotarget.7(26), 40756–40766 (2016).
   PubMedGoogle Scholar
• Qi WX , FuS, ZhangQet al. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Radiother. Oncol.114(3), 289–295 (2015).
   PubMed Web of Science ®Google Scholar
• Blettner M , SauerbreiW, SchlehoferBet al. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int. J. Epidemiol.28(1), 1–9 (1999).
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver . EASL clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol.69(1), 182–236 (2018).
   PubMed Web of Science ®Google Scholar